Metformin Ineffective for COVID Recovery, Trial Finds
July 17, 2025
-
3 min
A recent randomized clinical trial revealed that metformin does not significantly reduce the duration of COVID-19 symptoms in low-risk outpatients. Conducted with 2991 participants aged 30 and older across 90 US sites from September 2023 to May 2024, the study reported similar median recovery times of 9 days for metformin and 10 days for placebo. While metformin was well tolerated, the study found no significant differences in health outcomes or safety events, indicating the need for further investigation into its effects on COVID-19.
1. Metformin did not significantly reduce COVID-19 symptom duration. 2. Study conducted on 2991 participants aged 30 and older. 3. Median recovery time: 9 days for metformin, 10 for placebo. 4. Safety events were rare, with no cases of lactic acidosis. 5. Majority of participants had 2 or more COVID-19 vaccine doses. 6. Need for further studies noted for validation of findings.
Listen Tab content
